IGF-1R signaling can therefore limit the antiproliferative effects of gefitinib in vitro, and we speculate that for a subset of human breast cancers, adding an anti-IGF-1R strategy to gefitinib treatment may be more effective than a single-agent approach. Here, IGF1R is linked to breast cancer.